Hypertension, Pulmonary Clinical Trial
Official title:
A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension
Verified date | November 2021 |
Source | Eli Lilly and Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 year extension period (Period 2) during which participants will receive tadalafil.
Status | Completed |
Enrollment | 35 |
Est. completion date | March 10, 2021 |
Est. primary completion date | March 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 17 Years |
Eligibility | Inclusion Criteria: - =6 months to <18 years of age at screening - Currently have a diagnosis of PAH that is either: - idiopathic, including hereditary - related to connective tissue disease - related to anorexigen use - associated with surgical repair of at least 6-month duration of congenital systemic to pulmonary shunt (eg, atrial septal defect, ventricular septal defect, patent ductus arteriosus) - Have a history of a diagnosis of PAH established by a resting mean pulmonary artery pressure (mPAP) =25 millimeter of mercury (mm Hg), pulmonary artery wedge pressure =15 mm Hg, and a pulmonary vascular resistance (PVR) =3 Wood units via right heart catheterization (RHC). In the event that a pulmonary artery wedge pressure cannot be obtained during RHC, participants with a left ventricular end diastolic pressure (LVEDP) <15 mm Hg, with normal left heart function, and absence of mitral stenosis on echocardiography can be eligible for enrollment - Have a World Health Organization (WHO) functional class value of II or III at the time of screening - All participants must be receiving an endothelin receptor antagonist (ERA) (such as bosentan or ambrisentan) and must be on a maintenance dose with no change in dose (other than weight-based adjustments) for at least 12 weeks prior to screening and have a screening aspartate transaminase (AST)/alanine transaminase (ALT) <3 times the upper limit of normal (ULN) - If on conventional PAH medication, including but not restricted to, anticoagulants, diuretics, digoxin, and oxygen therapy, the participant must be on stable doses with no changes (other than weight-based adjustments) for at least 4 weeks before screening - Female participants of childbearing potential must test negative for pregnancy during screening. Furthermore, female participants must agree to abstain from sexual activity or to use two different reliable methods of birth control as determined by the Investigator during the study. Examples of reliable birth control methods include true abstinence as a lifestyle choice (periodic sexual abstinence method is not acceptable); the use of oral contraceptives; a reliable barrier method of birth control (diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices) - Written informed consent from parents (and written assent from appropriately aged participants) will be obtained prior to any study procedure being performed Exclusion Criteria: - Have pulmonary hypertension related to conditions other than specified above, including but not limited to chronic thromboembolic disease, portal pulmonary hypertension, left-sided heart disease or lung disease and hypoxia - History of left-sided heart disease, including any of the following: - clinically significant [pulmonary artery occlusion pressure (PAOP) 15-18 mm Hg] aortic or mitral valve disease (ie, aortic stenosis, aortic insufficiency, mitral stenosis, moderate or greater mitral regurgitation) - pericardial constriction - restrictive or congestive cardiomyopathy - left ventricular ejection fraction <40% by multigated radionucleotide angiogram (MUGA), angiography, or echocardiography - left ventricular shortening fraction <22% by echocardiography - life-threatening cardiac arrhythmias - symptomatic coronary artery disease within 5 years of study entry - Unrepaired congenital heart disease - Have a history of angina pectoris or other condition that was treated with long- or short-acting nitrates within 12 weeks before administration of study drug - Have severe hepatic impairment, Child-Pugh Grade C - Have severe renal insufficiency, defined as receiving renal dialysis or having a measured or estimated creatinine clearance (CC) <30 millimeter per minute (mL/min) (Schwartz Formula) - Diagnosed with a retinal disorder (eg, hereditary retinal disorders, retinopathy of the preterm participant and other retinal disorders) - Have severe hypotension or uncontrolled hypertension as determined by the Investigator - Have significant parenchymal lung disease - Have bronchopulmonary dysplasia - Concurrent phosphodiesterase type 5 (PDE5) inhibitor therapy (sildenafil or vardenafil) or has received PDE5 inhibitor therapy within 12 weeks prior to the first study drug dosing - Concurrent therapy with prostacyclin or its analogues within 12 weeks of screening - Commenced or discontinued a chronic conventional PAH medication including but not restricted to: diuretics, anti-coagulants, digoxin, and oxygen therapy within 4 weeks of screening - Currently receiving treatment with doxazosin, nitrates, or cancer therapy - Current treatment with potent Cytochrome P450 3A4 (CYP3A4) inhibitors, such as antiretroviral therapy (protease inhibitor), systemic ketoconazole, or systemic itraconazole, or chronic use of potent CYP3A4 inducers, such as rifampicin - Are nursing or pregnant - Have previously completed or withdrawn from this study (LVHV), or any other study investigating tadalafil - Have received tadalafil therapy within 12 weeks prior to the first study drug dosing or are hypersensitive to tadalafil - Have allergy to the excipients, notably lactose - Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study by the Sponsor - Unable to take orally administered tablets (without chewing, crushing or breaking) or suspension - Are Investigator site personnel directly affiliated with this study or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted - Diagnosis of Down syndrome |
Country | Name | City | State |
---|---|---|---|
Austria | AKH | Wien | |
Belgium | Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg | Leuven | |
Brazil | Irmandade da Santa Casa de Misericordia de Porto Alegre | Porto Alegre | Rio Grande Do Sul |
Brazil | Pronto Socorro Cardiologico de Pernambuco-PROCAPE | Recife | PE |
Brazil | Instituto Dante Pazzanese de Cardiologia | Sao Paulo | SP |
Brazil | UNIFESP - Escola Paulista de Medicina | Sao Paulo | SP |
France | CHU Hopital d'enfants de la Timone | Marseille Cedex 05 | |
France | GH Necker - Enfants Malades | Paris Cedex 15 | |
France | Hopital Haut Leveque - Group hospitalier Sud | Pessac | |
France | Chu de Toulouse - Hopital des Enfants | Toulouse Cedex 3 | |
Germany | Universitätsklinikum Heidelberg | Heidelberg | Baden-Württemberg |
Germany | Universitätsklinikum Ulm | Ulm | Baden-Württemberg |
Israel | Schneider Medical Center | Petah Tiqva | |
Israel | Sheba Medical Center | Tel Hashomer | Ramat Gan |
Italy | Istituto Giannina Gaslini Ospedale Pediatrico I.R.C.C.S. | Genova | GE |
Italy | Ospedale V. Monaldi | Napoli | |
Italy | Ospedale Bambino Gesu | Roma | |
Japan | Asahikawa Medical College Hospital | Asahikawa | Hokkaido |
Japan | Tokyo Metropolitan Children's Medical Center | Fuchu | Tokyo |
Japan | Okinawa Prefectural Nanbu Medical Center & Children's Med Ct | Haebaru-cho, Shimajiri-gun | Okinawa |
Japan | Toho University Omori Medical Center | Ohta-Ku | Tokyo |
Japan | National Center For Child Health And Development | Setagaya-ku | Tokyo |
Japan | Gunma Children's Medical Center | Shibukawa | Gunma |
Japan | Shizuoka Prefectural Children's Hospital | Shizuoka | |
Japan | Mie University Hospital | Tsu | Mie |
Mexico | Instituto Nacional de Cardiologia Ignacio Chavez | Ciudad de Mexico | DF |
Netherlands | Universitair Medisch Centrum Groningen | Groningen | |
Poland | Uniwersyteckie Centrum Kliniczne | Gdansk | |
Poland | Uniwersytecki Szpital Dzieciecy w Krakowie-Prokocimiu | Krakow | |
Poland | Instytut Pomnik-Centrum Zdrowia Dziecka | Warszawa | Woj Mazowieckie |
Poland | Wojewódzki Szpital Specjalistyczny we Wroclawiu | Wroclaw | |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Universitario Ramon y Cajal | Madrid | |
Turkey | Hacettepe University Faculty of Medicine | Ankara | |
Turkey | Gazi University Medical Faculty | Besevler/Ankara | |
United States | Children's Heathcare of Atlanta, Inc. at Egleston | Atlanta | Georgia |
United States | Cincinnati Childrens Hospital Medical Center | Cincinnati | Ohio |
United States | Nationwide Children's Hosp | Columbus | Ohio |
United States | Childrens Hospital of Michigan | Detroit | Michigan |
United States | Texas Childrens Hospital | Houston | Texas |
United States | Vanderbilt Univeristy School of Medicine | Nashville | Tennessee |
United States | Primary Childrens Medical Center | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Eli Lilly and Company |
United States, Austria, Belgium, Brazil, France, Germany, Israel, Italy, Japan, Mexico, Netherlands, Poland, Spain, Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters | 6MWD in meters assessed in a subset of participants who are =6 to <18 years of age who are developmentally capable of performing a 6MW test. Change from baseline was derived using mixed model repeated measures (MMRM) with terms for treatment group, visit, baseline 6MWD, and treatment-by-visit interaction. | Baseline, Week 24 | |
Secondary | Period 1: Time to Adjudicated Clinical Worsening (CW) | Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope,initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV;only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of = 20% in the 6 minute walk distance(for those participants who are =6 years of age). Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment. | Baseline through Week 24 | |
Secondary | Period 1: Percentage of Participants Who Experience CW | Clinical worsening was defined as any of the following: death,lung or heart transplantation,atrial septostomy or Potts' shunt,hospitalization for Pulmonary Arterial Hypertension(PAH) progression,new onset syncope, initiation of new PAH therapy(including increase in the dose of existing PAH specific concomitant therapy,such as endothelin receptor agonist or beraprost medication),or increase of 1 or more in World Health Organization(WHO) Functional Class(except for participants already in Class IV; only for participants unable to perform the 6 minute walk(6MW) test;worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk(6MW) test and who have a decrease of = 20% in the 6 minute walk distance(for those participants who are =6 years of age).Criteria for CW(from Period 1) were adjudicated by an independent,blinded study-specific Clinical Endpoint Committee(CEC).This adjudication was used for data analysis, and was not used to guide subject treatment. | Baseline through Week 24 | |
Secondary | Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at Steady-state | Period 1: Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil at steady-state | Week 2, Week 4, Week 16 and Week 24 | |
Secondary | Period 2: Percentage of Participants Who Experience CW | Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of = 20% in the 6 minute walk distance (for those participants who are =6 years of age). | Period 2 Baseline through Study Completion (Up to 24 Months) | |
Secondary | Period 2: Time to First Occurrence of CW | Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of = 20% in the 6 minute walk distance (for those participants who are =6 years of age). | Period 2 Baseline through Study Completion (Up to 24 Months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04095286 -
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
|
Phase 1 | |
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT02191137 -
Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
|
Phase 4 | |
Completed |
NCT01959828 -
Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery
|
Phase 3 | |
Withdrawn |
NCT01202045 -
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
|
N/A | |
Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 | |
Completed |
NCT01121458 -
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
|
Phase 4 | |
Terminated |
NCT00825266 -
Insulin Resistance in Pulmonary Arterial Hypertension
|
Phase 4 | |
Terminated |
NCT00384865 -
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
|
Phase 2 | |
Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
Completed |
NCT02826252 -
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
|
N/A | |
Completed |
NCT02545465 -
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
|
N/A | |
Recruiting |
NCT04498299 -
Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
|
||
Recruiting |
NCT02558582 -
Effect of Exercise Training in Patients With Pulmonary Hypertension
|
N/A | |
Active, not recruiting |
NCT02562235 -
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
|
Phase 3 | |
Completed |
NCT02755298 -
Chronic Clinical Effect of Acetazolamide
|
Phase 2/Phase 3 | |
Terminated |
NCT03043976 -
Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension
|
N/A | |
Completed |
NCT02576002 -
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
|
N/A | |
Completed |
NCT01317134 -
Endothelial Function in Patients With Pulmonary Arterial Hypertension
|
N/A |